Docoh
Loading...

ENZ Enzo Biochem

Employees

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years
DFAN14A
ENZ Enzo Biochem, Inc.
5 Jan 21
Additional proxy materials by non-management
3:04pm
DFAN14A
ENZ Enzo Biochem, Inc.
31 Dec 20
Additional proxy materials by non-management
5:01pm
DFAN14A
ENZ Enzo Biochem, Inc.
29 Dec 20
Additional proxy materials by non-management
7:00pm
DFAN14A
ENZ Enzo Biochem, Inc.
28 Dec 20
Additional proxy materials by non-management
7:00pm
DFAN14A
ENZ Enzo Biochem, Inc.
28 Dec 20
Additional proxy materials by non-management
8:30am
DFAN14A
ENZ Enzo Biochem, Inc.
23 Dec 20
Additional proxy materials by non-management
5:26pm
PREC14A
ENZ Enzo Biochem, Inc.
11 Dec 20
Preliminary proxy with contested solicitation
5:15pm
DFAN14A
ENZ Enzo Biochem, Inc.
9 Dec 20
Additional proxy materials by non-management
2:00pm
DFAN14A
ENZ Enzo Biochem, Inc.
20 Feb 20
Additional proxy materials by non-management
3:15pm
DFAN14A
ENZ Enzo Biochem, Inc.
19 Feb 20
Additional proxy materials by non-management
5:29pm
DFRN14A
ENZ Enzo Biochem, Inc.
11 Feb 20
Revised proxy by non-management
5:20pm
DFAN14A
ENZ Enzo Biochem, Inc.
6 Feb 20
Additional proxy materials by non-management
5:17pm
DFAN14A
ENZ Enzo Biochem, Inc.
6 Feb 20
Additional proxy materials by non-management
5:11pm
DFAN14A
ENZ Enzo Biochem, Inc.
29 Jan 20
Additional proxy materials by non-management
4:44pm
DFAN14A
ENZ Enzo Biochem, Inc.
27 Jan 20
Additional proxy materials by non-management
11:27am
DFAN14A
ENZ Enzo Biochem, Inc.
21 Jan 20
Additional proxy materials by non-management
4:36pm
DFAN14A
ENZ Enzo Biochem, Inc.
17 Jan 20
Additional proxy materials by non-management
4:29pm
DFAN14A
ENZ Enzo Biochem, Inc.
16 Jan 20
Additional proxy materials by non-management
5:18pm
DFAN14A
ENZ Enzo Biochem, Inc.
16 Jan 20
Additional proxy materials by non-management
5:15pm
DFAN14A
ENZ Enzo Biochem, Inc.
14 Jan 20
Additional proxy materials by non-management
5:15pm
DFAN14A
ENZ Enzo Biochem, Inc.
13 Jan 20
Additional proxy materials by non-management
9:18am
DFAN14A
ENZ Enzo Biochem, Inc.
9 Jan 20
Additional proxy materials by non-management
8:32pm
DFAN14A
ENZ Enzo Biochem, Inc.
8 Jan 20
Additional proxy materials by non-management
5:30pm
DFAN14A
ENZ Enzo Biochem, Inc.
8 Jan 20
Additional proxy materials by non-management
3:18pm
DFAN14A
ENZ Enzo Biochem, Inc.
3 Jan 20
Additional proxy materials by non-management
10:01am
DFAN14A
ENZ Enzo Biochem, Inc.
30 Dec 19
Additional proxy materials by non-management
12:43pm
DFAN14A
ENZ Enzo Biochem, Inc.
17 Dec 19
Additional proxy materials by non-management
4:58pm
DFAN14A
ENZ Enzo Biochem, Inc.
9 Dec 19
Additional proxy materials by non-management
2:59pm
PREC14A
ENZ Enzo Biochem, Inc.
20 Nov 19
Preliminary proxy with contested solicitation
5:26pm
PREC14A
ENZ Enzo Biochem, Inc.
15 Nov 19
Preliminary proxy with contested solicitation
2:30pm
DFAN14A
ENZ Enzo Biochem, Inc.
17 Sep 19
Additional proxy materials by non-management
3:00pm
Vote support at last AGM


The Company held its Annual Meeting of Shareholders (the “Annual Meeting”) on January 4, 2021. As of November 23, 2020, the record date for the Annual Meeting, there were a total of 47,895,050 shares of Common Stock outstanding and entitled to vote at the Annual Meeting. There were present at the meeting either in person, online, or by valid proxy, the holders of 30,824,490 shares of Common Stock, and, therefore, a quorum was present. Set forth below are the proposals voted upon at the Annual Meeting and the final voting results as certified by the independent inspector of elections. For more information about any of the proposals voted on at the Annual Meeting, please see the Proxy Statement.

Proposal 1 – Election of the nominees listed below:

(a) Class III Directors:

NomineeVotes ForAgainstAbstentionsBroker Non-Vote
Elazar Rabbani, Ph.D.10,499,42013,430,432195,9731,425,621
Ian Walters, M.D.23,844,4935,414,177140,1991,425,621


(b) Class II Director:

NomineeVotes ForAgainstAbstentionsBroker Non-Vote
Mary Tagliaferri, M.D.18,569,5545,418,300137,9711,425,621


On the basis of the above votes, (i) Dr. Walters was elected to serve as a Class III Director on the Board of Directors of the Company (the “Board”), to hold office for a term of three (3) years or until his respective successor has been duly elected and qualified; and (ii) Dr. Tagliaferri was elected to serve as a Class II Director on the Board, to hold office for a term of two (2) years or until her respective successor has been duly elected and qualified.

Dr. Rabbani did not receive a majority of the votes cast in the affirmative and, pursuant to the terms of the Company’s Amended and Restated By-laws (the “By-Laws”), conditionally tendered his resignation to the Board, with the effectiveness of such resignation being conditioned on the Board’s acceptance of such resignation in accordance with the By-Laws. The Nominating/Governance Committee of the Board will consider Dr. Rabbani’s resignation and make a recommendation to the Board on whether to accept or reject such resignation, or whether other action should be taken. The Board has 90 days from the date of certification of the election results to determine what action to take with respect to Dr. Rabbani’s resignation. The Board will publicly disclose its decision through the filing of a Current Report on Form 8-K. Dr. Rabbani will continue to serve as a director pending the Board’s determination with respect to his conditional resignation.

Proposal 2 – Approve, in a non-binding advisory vote, the compensation of the Company’s named executive officers:

Votes for10,557,570
Votes against18,561,860
Abstentions279,439
Broker Non-Votes1,425,621


On the basis of the above votes, the proposal to approve, in a nonbinding advisory vote, the compensation of the Company’s named executive officers was not approved.



Proposal 3 – Ratification of the Company’s appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending July 31, 2021:

Votes for30,200,549
Votes against496,499
Abstentions127,442
Broker non-votes.(0)


On the basis of the above votes, the proposal to ratify the Company’s appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the Company’s fiscal year ending July 31, 2021 was approved.

Proposal 4 – Approve the amendment and restatement of the Company’s Amended and Restated 2011 Incentive Plan, including an increase in the number of shares of Common Stock authorized for grant under such plan:

Votes for21,777,014
Votes against7,148,001
Abstentions473,854
Broker non-votes.1,425,621


On the basis of the above votes, the proposal to approve the amendment and restatement of the Company’s Amended and Restated 2011 Incentive Plan was approved.